Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel therapies in oncology and obesity through innovative approaches to validated biological pathways. The company's lead programs include CRB-701, an antibody-drug conjugate targeting Nectin-4 on cancer cells with improved tolerability versus existing therapies, and CRB-913, an oral CB1 receptor inverse agonist for weight loss designed for patients who do not respond to or tolerate GLP-1 drugs. As a pre-commercial company, Corbus funds operations through research and development expenditures, relying on contract manufacturers and licensing partners for drug supply and manufacturing, with future revenue expected to derive from product commercialization upon regulatory approval.